U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Gain of Chromosome 1q21

MedGen UID:
1386239
•Concept ID:
C4330030
•
Cell or Molecular Dysfunction
Synonym: 1q21 Amplification

Definition

A cytogenetic abnormality that refers to allelic gain within the chromosomal region 1q21. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGain of Chromosome 1q21

Professional guidelines

PubMed

Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Daudignon A, Cuccuini W, Bracquemart C, Godon C, Quilichini B, Penther D
Curr Res Transl Med 2023 Oct-Dec;71(4):103427. Epub 2023 Oct 24 doi: 10.1016/j.retram.2023.103427. PMID: 38035476
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J
Am J Hematol 2016 Nov;91(11):E473-E477. Epub 2016 Sep 3 doi: 10.1002/ajh.24533. PMID: 27508939

Recent clinical studies

Etiology

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM
Blood Cancer J 2024 Apr 22;14(1):69. doi: 10.1038/s41408-024-01030-w. PMID: 38649340Free PMC Article
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR
Blood Cancer J 2024 Jan 25;14(1):20. doi: 10.1038/s41408-024-00985-0. PMID: 38272897Free PMC Article
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH
Transplant Cell Ther 2023 Dec;29(12):757-762. Epub 2023 Sep 4 doi: 10.1016/j.jtct.2023.08.031. PMID: 37673125
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Chromosome 1q21 abnormalities in multiple myeloma.
Schmidt TM, Fonseca R, Usmani SZ
Blood Cancer J 2021 Apr 29;11(4):83. doi: 10.1038/s41408-021-00474-8. PMID: 33927196Free PMC Article

Diagnosis

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM
Blood Cancer J 2024 Apr 22;14(1):69. doi: 10.1038/s41408-024-01030-w. PMID: 38649340Free PMC Article
Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain.
Iriuchishima H, Saito A, Mihara M, Terasaki Y, Matsumoto A, Isoda A, Furukawa Y, Matsumoto M
Int J Hematol 2024 Jul;120(1):71-79. Epub 2024 Mar 29 doi: 10.1007/s12185-024-03760-w. PMID: 38551778
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH
Transplant Cell Ther 2023 Dec;29(12):757-762. Epub 2023 Sep 4 doi: 10.1016/j.jtct.2023.08.031. PMID: 37673125
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Chromosome 1q21 abnormalities in multiple myeloma.
Schmidt TM, Fonseca R, Usmani SZ
Blood Cancer J 2021 Apr 29;11(4):83. doi: 10.1038/s41408-021-00474-8. PMID: 33927196Free PMC Article

Therapy

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM
Blood Cancer J 2024 Apr 22;14(1):69. doi: 10.1038/s41408-024-01030-w. PMID: 38649340Free PMC Article
Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain.
Iriuchishima H, Saito A, Mihara M, Terasaki Y, Matsumoto A, Isoda A, Furukawa Y, Matsumoto M
Int J Hematol 2024 Jul;120(1):71-79. Epub 2024 Mar 29 doi: 10.1007/s12185-024-03760-w. PMID: 38551778
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR
Blood Cancer J 2024 Jan 25;14(1):20. doi: 10.1038/s41408-024-00985-0. PMID: 38272897Free PMC Article
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH
Transplant Cell Ther 2023 Dec;29(12):757-762. Epub 2023 Sep 4 doi: 10.1016/j.jtct.2023.08.031. PMID: 37673125
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article

Prognosis

Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR
Blood Cancer J 2024 Jan 25;14(1):20. doi: 10.1038/s41408-024-00985-0. PMID: 38272897Free PMC Article
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.
Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH
Blood Cancer J 2024 Jan 10;14(1):4. doi: 10.1038/s41408-023-00973-w. PMID: 38199987Free PMC Article
PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion.
Xu J, Wang Y, Li P, Chen C, Jiang Z, Wang X, Liu P
Br J Haematol 2023 Nov;203(4):599-613. Epub 2023 Sep 4 doi: 10.1111/bjh.19088. PMID: 37666675
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Chromosome 1q21 abnormalities in multiple myeloma.
Schmidt TM, Fonseca R, Usmani SZ
Blood Cancer J 2021 Apr 29;11(4):83. doi: 10.1038/s41408-021-00474-8. PMID: 33927196Free PMC Article

Clinical prediction guides

Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study.
Facon T, Moreau P, Špicka I, Suzuki K, Yong K, Mikhael J, Fukao T, Bisht K, Armstrong NM, Macé S, Risse ML, Martin T
Hematol Oncol 2024 Mar;42(2):e3258. doi: 10.1002/hon.3258. PMID: 38402467
Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Daudignon A, Cuccuini W, Bracquemart C, Godon C, Quilichini B, Penther D
Curr Res Transl Med 2023 Oct-Dec;71(4):103427. Epub 2023 Oct 24 doi: 10.1016/j.retram.2023.103427. PMID: 38035476
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I
Int J Hematol 2022 Jun;115(6):762-777. Epub 2022 May 9 doi: 10.1007/s12185-022-03353-5. PMID: 35534749Free PMC Article
Chromosome 1q21 abnormalities in multiple myeloma.
Schmidt TM, Fonseca R, Usmani SZ
Blood Cancer J 2021 Apr 29;11(4):83. doi: 10.1038/s41408-021-00474-8. PMID: 33927196Free PMC Article
Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
Wang Y, Li Q, Xing S, Zhang H, Li D
Clin Lymphoma Myeloma Leuk 2019 Sep;19(9):e545-e550. Epub 2019 May 29 doi: 10.1016/j.clml.2019.05.016. PMID: 31262667

Recent systematic reviews

Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR
Blood Cancer J 2024 Jan 25;14(1):20. doi: 10.1038/s41408-024-00985-0. PMID: 38272897Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...